drugset / Trial / NCT03273712
Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)
Phase 2
Completed
39 enrolled
University of Iowa
National Cancer Institute (NCI) · collabNational Institutes of Health (NIH) · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase 2 peptide receptor radionuclide therapy trial of 90Y-DOTATOC in patients with somatostatin receptor positive tumors.
Timeline
- Start
- 2017-09-29
- Primary completion
- 2020-05-27
- Completion
- 2020-05-27
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Background | L-arginine | Small molecule | — | — |
| Background | Lysine | Other / unclassified | — | — |